Quantcast

Latest CytRx Stories

2014-10-20 08:30:08

LOS ANGELES, Oct. 20, 2014 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society. The paper discusses results from CytRx's completed Phase 1b/2 clinical trial where 25 patients were enrolled, including...

2014-10-17 08:25:10

Trial Has Not Yet Reached Necessary Number of Survival Events to Report on Overall Survival Due to Longer than Expected Survival of Study Patients LOS ANGELES, Oct. 17, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that data regarding the Company's Phase 2b global clinical trial of aldoxorubicin for the treatment of first-line soft tissue sarcoma (STS) will be presented in a moderated...

2014-10-16 08:30:19

LOS ANGELES, Oct. 16, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its Board of Directors has appointed Steven A. Kriegsman, President, Chief Executive Officer and a Director of the Company, as Chairman of the Board, effective October 15, 2014. He replaces Max E. Link, Ph.D. whose unexpected passing was announced on October 7, 2014. "I am honored to assume the additional...

2014-10-13 08:26:19

Expected to Yield First Clinical Candidate in 2015 LOS ANGELES, Oct. 13, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has commenced operations at its new discovery laboratory, located in Freiburg, Germany. The new laboratory will conduct discovery and translational research to create drug candidates that utilize novel linker technologies that couple chemotherapeutic...

2014-10-09 08:26:38

LOS ANGELES, Oct. 9, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors. Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin. The Phase 1b...

2014-10-08 16:26:59

LYNBROOK, N.Y., Oct. 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), today announced with great sadness that Max Link, Ph.D., a member of its Board of Directors, passed away unexpectedly on October 5, 2014. He was 74 years old. Dr. Link served as the Chair of the Compensation Committee, as the Audit Committee Financial Expert and as a member of the Board's Audit, Compensation and Nominating and Corporate Governance Committees. "We are very saddened by the...

2014-10-07 16:27:01

LOS ANGELES, Oct. 7, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced Max E. Link, Ph.D., Chairman of the Board of Directors, passed away unexpectedly at the age of 74. "We are deeply saddened by the loss of our dear friend and colleague, and our thoughts are with his family during this difficult time," said Steven A. Kriegsman, CytRx President and Chief Executive Officer. "Max was a...

2014-09-30 08:30:56

Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy....

2014-09-29 08:29:30

Follows CytRx's Strategy to Develop a Global Oncology Franchise in Numerous Orphan Indications LOS ANGELES, Sept. 29, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung...

2014-09-26 08:24:55

Presentation and Webcast Scheduled for September 26th at 3:30 PM ET LOS ANGELES, Sept. 26, 2014 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced a change in the Company's presentation time at BioCentury's 2014 NewsMakers in the Biotech Industry Conference. David J. Haen, Vice President, Business Development, will present on Friday, September 26(th) at 3:30 p.m. ET. A live and archived...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.